Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Harmony Biosciences is a U.S. pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders and other central nervous system (CNS) diseases. Headquartered in Plymouth Meeting, PA, their flagship product is WAKIX® (pitolisant), a first-in-class medication approved for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. Harmony Biosciences is committed to advancing scientific understanding and addressing unmet medical needs within the neuroscience space, aiming to improve the lives of patients with often underserved conditions.
The headquarters serves as the primary center for Harmony Biosciences' executive leadership, corporate strategy, commercial operations, clinical development oversight, financial management, and administrative functions.
The headquarters is located in a modern office park, likely featuring contemporary office designs, collaborative workspaces, and technology infrastructure necessary for a pharmaceutical company. Specific unique architectural details are not widely publicized.
The work culture at Harmony Biosciences is expected to be patient-centric, science-driven, and collaborative, emphasizing innovation, integrity, and a commitment to addressing unmet medical needs in neurological disorders. Employees likely experience a dynamic environment focused on growth and impact.
This central location is critical for coordinating all aspects of the company's operations, from research and development partnerships to the commercialization strategy for WAKIX® and future pipeline products in the U.S. market.
Harmony Biosciences' primary commercial focus is currently within the United States for its flagship product, WAKIX®. However, the company engages in global partnerships for drug development; for instance, pitolisant (the active ingredient in WAKIX®) was originally developed by Bioprojet in France and licensed to Harmony for the U.S. market. Harmony Biosciences has also acquired rights to develop and commercialize pitolisant in Latin America, signaling strategic intent for future international expansion. Their clinical development programs may also involve international research sites and collaborations.
630 W. Germantown Pike, Suite 215
Plymouth Meeting
Pennsylvania
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Harmony Biosciences' leadership includes:
Harmony Biosciences has been backed by several prominent investors over the years, including:
In the past 12 months (since May 2023), Harmony Biosciences has strengthened its executive team with the key appointment of a Chief Corporate Affairs Officer, reflecting its ongoing growth and strategic priorities. There have been no major publicly announced executive departures during this period.
Discover the tools Harmony Biosciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Harmony Biosciences most commonly uses the [first_initial][last]@harmonybiosciences.com email format. This is a frequent pattern in many corporations, including those in the pharmaceutical sector.
[first_initial][last]@harmonybiosciences.com
Format
jdayno@harmonybiosciences.com
Example
85%
Success rate
ir.harmonybiosciences.com • May 7, 2024
Harmony Biosciences announced its financial results for the first quarter ended March 31, 2024, reporting $168.7 million in net revenue for WAKIX® and reiterating its full-year 2024 financial guidance. The company also provided updates on its clinical development pipeline....more
ir.harmonybiosciences.com • February 20, 2024
The company reported strong financial performance for the fourth quarter and full-year 2023, with WAKIX® net revenue of $167.8 million for Q4 and $582.1 million for the full year. Progress in R&D programs for rare neurological diseases was also highlighted....more
ir.harmonybiosciences.com • January 8, 2024
Harmony Biosciences outlined its strategic priorities for 2024, including maximizing WAKIX®'s potential, advancing its pipeline candidates like pitolisant in Prader-Willi syndrome and Myotonic Dystrophy Type 1, and pursuing business development for long-term growth....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Harmony Biosciences, are just a search away.